Mocetinostat – 25 mg

Brand:
Cayman
CAS:
726169-73-9
Storage:
-20
UN-No:
Non-Hazardous - /

Mocetinostat is an orally available inhibitor of histone deacetylases (HDACs) that selectively targets HDAC1 and 2 (IC50s = 0.15 and 0.29 µM, respectively), less potently inhibits HDAC3 and 11 (IC50s = 1.66 and 0.59 µM, respectively) and has negligible actions against HDAC4-8.{29774,29775} It induces hyperacetylation of histones, causes cell cycle blockade, and induces apoptosis in cancer cells in vitro.{29774,29773} Mocetinostat also has antitumor activity in vivo, blocking the growth of human tumor xenografts in mice.{29774} It also significantly reduces cardiac fibrosis following ischemic heart failure in mice.{29776}  

 

Available on backorder

SKU: - Category:

Description

An orally available HDAC inhibitor that selectively targets HDAC1 and 2 (IC50s = 0.15 and 0.29 µM, respectively), less potently inhibits HDAC3 and 11 (IC50s = 1.66 and 0.59 µM, respectively); induces hyperacetylation of histones, causes cell cycle blockade, and induces apoptosis in cancer cells in vitro


Formal name: N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-benzamide

Synonyms:  ​MGCD0103

Molecular weight: 396.4

CAS: 726169-73-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cardiovascular System|Cardiovascular Diseases|Heart Failure||Research Area|Cardiovascular System|Heart||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Deacetylation